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Abstract
Background: Cytochrome P450 CYP1A1 helps detoxify the potential carcinogens in tobacco smoke, it was reported
that polymorphisms in the coding gene result in variation in the expression and activity levels which alter metabolism
and clearance of carcinogens and therefore modify cancer risk. In this work, we aimed to identify CYP1A1 gene
polymorphisms associated with lung cancer in Egyptian population and to examine the interaction effect with
Tobacco smoking in modulating disease risk.
Methods: A case–control study was conducted on 150 unrelated lung cancer patients and 150 unrelated control
subjects. Genomic DNA was extracted and sequencing analysis of CYP1A1 gene was performed on ABI PRISM 3100
genetic analyzer.
Results: Three variants in CYP1A1 gene were identified in heterozygous forms in lung cancer patients I462V,
T461N and I286T. A combined variant T461N/ I462V associated with lung cancer and those who carried this
variant were 2-times more likely to develop lung cancer (OR = 2.03, 95% CI = 1.81-2.29, P = 0.04), specially the
non-small cell type (NSCLC) (OR = 2.20, 95% CI = 1.93–2.50, P = 0.02). Wild type was more frequent among
smoker controls (83.3%) compared to smoker lung cancer patients (54.8%), P = 0.03. Association studies to
examine the interaction effect of identified variants with Tobacco smoking in modulating disease risk showed
no significant associations. Identified polymorphisms showed no significant implication on the stage or the
prognosis of the disease.
Conclusion: Our findings support that CYP1A1 polymorphisms play a role in the pathogenesis of lung cancer. In
Egyptian population, CYP1A1 I462V, T461N and I286T variants were identified among lung cancer patients and combined
T461N/ I462V was a risk variant for NSCLC in non smokers.
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Background
Lung cancer progression is characterized by cumulative
alterations in key molecules involved in the cell cycle,
signaling and angiogenesis pathways. Most lung cancer
patients demonstrate chromosomal abnormalities at the
site of tumor suppressor genes or have mutations in
known oncogenes [1].
In the laboratory, chemicals in tobacco reduce the
capacity to repair DNA damage in cells from lung cancer
patients than cells from normal individuals [2]. As many
smokers do not develop lung cancer, it is likely that inher-
ited factors influence the effects of tobacco. There is a
considerable interest in variants of genes that help detox-
ify the carcinogens in tobacco smoke, such as members of
the cytochrome P450 (CYP), glutathione S-transferase
(GST) and N-acetyltransferase (NAT) gene families [3].
Scientists have identified 57 human CYP genes and 33
pseudo genes divided into 18 families and 42 subfamilies.
Now CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C9,
CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and other
gene polymorphisms have been confirmed and specific
metabolic enzyme phenotypes differ with regions and
races [4]. CYP gene changes can cause increased activity
of the enzyme, decreased activity or even inactivity. In
addition, mutations at the substrate recognition sites may
lead to changes in enzyme specificity [5].
CYP1A1 plays a major role as a carcinogen activating
enzyme within the CYP system. Unlike most CYP
enzymes, CYP1A1 expression is mainly found in extra
hepatic tissues, including the lung, where it metabolizes
and is markedly induced by polycyclic aromatic hydrocar-
bons (PAHs) [6]. Elevated CYP1A1 inducibility is associ-
ated with pulmonary PAH-related DNA adduction [7] and
high lung cancer risk [8]. Both CYP1A1 expression and
the formation of these PAH-DNA adducts in human lung
tissue are highly variable [9–11], possibly due to differing
exposure to environmental factors and to genetic poly-
morphisms affecting the CYP1A1 gene locus [12].
The first variant allele identified was CYP1A1*2A
(MspI or m1 polymorphism) and is found in 5% of
Caucasians [13]. CYP1A1*2C (Ile462Val or m2 poly-
morphism) is rare in Caucasians and is usually detected
with CYP1A1*2A [14]. The combination of both variants
is referred to as CYP1A1*2B. CYP1A1*3, consisting of a
T3205C base change (m3), seems to show enhanced en-
zyme activity, although it is extremely uncommon in
Caucasians [13]. Finally, CYP1A1*4, a Thr461Asn (m4)
amino acid change, detected in Caucasians with a fre-
quency of roughly 3%, has also been related to greater
enzyme catalytic efficiency [15]. These CYP1A1 poly-
morphisms have been extensively studied with regard to
risk of lung cancer. However, whereas some studies re-
port increased risk in the presence of some of the muta-
tions [16, 17], there are many other contradictory results
due to ethnic differences [18, 19].
The aim of this work is to identify CYP1A1 gene poly-
morphisms associated with lung cancer in Egyptian
population and to examine the interaction effect with
Tobacco smoking in modulating disease risk.
Methods
Subjects
This work was collaboration between National Cancer
Institute (NCI) and National Research Center (NRC),
Cairo, Egypt. A case–control study was conducted on
150 unrelated adult patients with primary lung cancer
and 150 unrelated controls. Patients were presented
to NCI from different governorates of Egypt; Cairo,
Giza, Qalyubia, Sharqia, Monufia, Kafr El-Sheikh,
Minya, Faiyum, Asyut, Sohag and Qena. All subjects
included in the study were interviewed to fill a med-
ical questionnaire with special consideration to the
lifetime history of tobacco use, residence, occupa-
tional history and family history of cancer. Thorough
Table 1 Primers used for amplification and direct sequencing





1A1 ex1-S CCGAGTCCTGGTAGGCTGTA 5′-fanking Exon 1
1A1 ex1-A CCTGCAGTTGGCAATCTGTC intron 1
1A1 ex2-S CCCACAGTGGTAGTTCAACA intron 1 Exon 2
1A1 ex2-A CCCTGCCAAGGAAGAAGACT intron 2
1A1 ex3-S AGAGCCTTGCAGAGGCAGAG intron 2 Exons 3–6
1A1 ex6-A GGCAATGGTCTCACCGATAC exon 6
1A1 I462V-S GCTGCTTGCCTGTCCTCTAT intron 6 Exon 7a
1A1 I462V-A AGGCATGCTTCATGGTTAGC exon 7
1A1 ex7-S AGCTATGGGTCAACCCATCT exon 7 Exon 7b
1A1 ex7-A TCTTCTTCCTCCCTACAGTA intron 7
Fig. 1 2% agarose gel illustrating the amplification of CYP1A1 gene
in two patients. Lanes 1 and 6: amplification of exon 1 (1153-bp).
Lanes 2 and 7: amplification of exon 2 (1180-bp). Lane 3 and 8:
amplification of exons 3–6 (1233-bp). Lanes 4 and 9: amplification of
exon 7a (349-bp). Lanes 5 and 10: amplification of exon 7b (1330-
bp). M: Size marker (PhiX174 DNA/HaeIII digest)
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clinical examination and chest radiography were ap-
plied. Blood sample was obtained from each subject
for sequencing analysis of the human CYP1A1 gene.
Sample for histopathology examination of cancer was
obtained from each patient either by open biopsy or
via bronchoscopy. The exclusion criteria included pre-
vious history of cancer, metastasized cancer from
other organs, patients with pulmonary fibrosis, acute
interstitial pneumonia and previous radiotherapy or
chemotherapy or receiving any anti-cancer treatment
before enrollment in the study. The study was approved
by the ethics committee of the National Research Center.
All subjects were aware by the nature of the study and
gave a written informed consent.
Methodology
DNA extraction
Genomic DNA was extracted from blood samples ob-
tained from 150 controls and 150 lung cancer patients
using QIAamp DNA extraction kit (Qiagen Hilden,
Germany, Cat no. 51304) according to the manufacturer's
instructions.
Sequence analysis of the CYP1A1 gene
The sequence of the human CYP1A1 gene described in
the GenBank (accession number X02612) was used as a
reference. The primers used for the amplification and
the direct sequencing of all seven exons and exon-intron
junctions of the gene are shown in Table 1. PCR for each
fragment of CYP1A1 gene was conducted in a 25 μl re-
action mixture containing 100 ng of genomic DNA, 20
pmol of each primer and 12.5 μl of AmpliTaq Gold 360
Master Mix (Applied BioSystems, Foster City, CA,
USA). PCR cycling conditions consisted of initial de-
naturation at 94 °C for 5 min, followed by 30 cycles of
denaturation at 94 °C for 30s, annealing at 60 °C for 30s
and extension at 72 °C for 30s, followed by a final exten-
sion of 5 min at 72 °C. PCR products were checked first
on 2% agarose gel for successful amplification (Fig. 1)
and was further purified using PureLink Quick PCR
Purification Kit (Invitrogen, Germany). The purified PCR
products were directly sequenced in both directions using
the Big Dye Termination kit (Applied Biosystems, Foster
City, CA, USA) and sequences were determined using
ABI PRISM 3100 genetic analyzer (Applied Biosystems).
Statistical analysis
Data were analyzed using SPSS version 18.0 (Chicago, IL,
USA). Data were expressed as number and percentage of
total for categorical variables. Chi-square test (χ2) was
used to compare the distribution of CYP1A1 genotypes
between groups. Likelihood ratio was used when the ex-
pected count was less than 5 in more than 20% of the
cells. The associations between genotype and risk of lung
cancer were estimated by odds ratio (OR) and 95% confi-
dence interval (95% CI) using logistic regression models.
The ORs were adjusted for age, smoking status, and pack-
years. P-value <0.05 was considered significant.
Wild c.1382C>A (T461N)
Fig. 2 Portion of the sequencing phoregram of exon7 of CYP1A1 gene showing the c.1382C > A (T461N) polymorphism. The arrow indicates the
site of the variant nucleotide position
Wild Variant c.1384A>G (I462V)
Fig. 3 Portion of the sequencing phoregrams of exon 7 of CYP1A1 gene showing the c.1384A > G (I462V) polymorphism. The arrow indicates the
site of the variant nucleotide position
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Results
The study included 300 subjects; 150 unrelated lung
cancer patients and 150 unrelated control subjects. A
statistical significant age difference was found between
controls (mean 43.3 ± 11.1 years) and patients (mean
56.7 ± 9.79 years) (p < 0.001), denoting that older age is
associated with higher risk of lung cancer. There was a
statistical significant difference in gender between the
two groups with 51.3% females and 48.7% males in con-
trol group vs. 24% females and 76% males in patients
group (X2 = 25.82, P < 0.0001), with 3.5-times increased
risk to develop lung cancer in males than in females
(OR = 3.49, CI: 2.13–5.69).
Mean pack-years was significantly higher in patients
(21.4 ± 2.25) than in controls (4.0 ± 0.77). Smoking
habit was significantly higher among patients (X2 = 56.88,
P < 0.0001), with an odd ration of 6.69 (CI: 3.99–11.20)
denoting a higher risk to develop lung cancer in smokers
by 6.7 times the non-smokers.
Our sequencing analysis of CYP1A1 gene identified
2 variants in exon7 in control subjects; CYP1A1*4
1382C > A (T461N) (n = 33) (Fig. 2) and CYP1A1*2C
1384A > G (I462V) (n = 19) (Fig. 3). In lung cancer
patients, 3 variants were identified, CYP1A1*2C (n = 17),
CYP1A1*4 (n = 46) and combined CYP1A1*2C/ CYP1A1*4
(n = 4). The very low frequent variant in the database
CYP1A1 857 T > C (I286T), which was found only 2 times
in thousands of human genomes, has been detected in
exons 3–6 of the CYP1A1 gene in a non-smoker adeno-
carcinoma case (Fig. 4). All identified variants were
detected in the heterozygous form.
There was no significant difference between controls
and lung cancer patients regarding the frequency of
identified CYP1A1 variants, except for the combined
variants CYP1A1*2C/ CYP1A1*4 which associated with
2-times higher risk of lung cancer (OR = 2.03, 95%
C.I:1.81–2.29, P = 0.04), specially the non-small cell type
(NSCLC) (OR = 2.20, 95% C.I: 1.93–2.50, P value = 0.02)
(Table 2) with no significant difference between the
pathological subtypes of NSCLC (P > 0.05).
There was statistical significant difference in the
distribution of CYP1A1 variants in relation to smok-
ing habit among lung cancer patients and control
subjects. The wild type gene was the most frequent
among smoker controls compared to non-smoker
controls and lung cancer patients (P = 0.03) (Table 3).
Association studies of CYP1A1 polymorphisms and
smoking with susceptibility to lung cancer showed no
significant association with disease risk (Table 4). No
significant association of CYP1A1 polymorphisms and
pack year with susceptibility to lung cancer (Table 5).
Identified polymorphisms showed no significant impli-
cation on the stage or the prognosis of the disease
(Tables 6 and 7).
Fig. 4 Portion of the sequencing phoregram of exons 3–6 of CYP1A1 gene showing c.857 T > C (I286T) polymorphism found in only one subject.
The arrow indicates the site of the variant nucleotide position
Table 2 Frequency of CYP1A1 variants among lung cancer patients and control
CYP1A1 Controla Casesa OR (95% CI) NSCLCa OR (95% CI) SCLCa OR (95% CI)
Variant n=150 n=149b P- value n=129 P value n=20 P- value

























SCLC small cell lung cancer, NSCLC non-small cell lung cancer
aData presented as N (%)
bThe case carrying rare CYP1A1 857 T > C (I286T) variant was excluded from the statistical analysis
csignificant p
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Discussion
CYP1A1 is a polymorphic gene located at 15q24.1 with 7
exons and 6 introns. In addition to the wild-type
(CYP1A1*1), 10 variant alleles have been identified [7].
Variants CYP1A1*2A, CYP1A1*2C, CYP1A1*3 and
CYP1A1*4 with trivial names m1, m2, m3 and m4;
respectively were the most commonly studied for cancer
link [20, 21].
About 90% of lung cancer is strongly associated with
Tobacco smoking [22]. Our results showed an estimated
risk for lung cancer 6.7 times greater in Egyptian
smokers than in non-smokers compared to 2.61 times in
a previous study [23] and an increased risk to develop
lung cancer in males by 3.5-times than in females, which
might be attributed to the higher incidence of smoking
habit among males.
In our patients, three polymorphisms in CYP1A1 gene
were identified; CYP1A1*2C (I462V) was detected in
12.7% of control subjects and 11.4% of patients, and
CYP1A1*4 (T461N) identified in 22% of controls and
30.9% of patients. In one non-smoker adenocarcinoma
patient, the rare CYP1A1 857 T > C (I286T) was identi-
fied. Ethnic difference in the distribution of CYP1A1*2C
variant has been demonstrated in lung cancer patients,
while few reports are available for CYP1A1*4. Frequen-
cies of CYP1A1*2C ranged from 2.2% to 8.9% in Caucasians
and was about 19.8% in Japanese, while CYP1A1*4 allele
was found in 2% to 5.7% of a Caucasian population
[24–27]. Asian reports rarely observed presence of
CYP1A1*4 variant [21, 28, 29], meanwhile, it was more
common among whites [30] and it was reported, by itself,
as a lung cancer risk factor in Caucasians [12].
CYP1A1*2C and *4 variants have generally been asso-
ciated with moderate to high risk of lung cancer [21].
These variants are rare in Caucasians and African-
Americans. While studies of African-Americans have re-
ported predominantly negative findings [31, 32], studies
of Caucasians have been mixed [33, 34]. Although I462V
polymorphism is relatively frequent in Asian populations
(18% to 25%), the Val allele is rare in Caucasian control
populations, occurring in 7% to 13% of people [35–37]
which agreed with obtained results in our control popu-
lation (12.7%).
In the studied Egyptian population, combined variant
T461N/ I462V (m2/m4) was found in 2.7% of lung cancer
patients associated with 2-times higher risk to develop
lung cancer compared to either control or individual m2
or m4 variant carriers.
In an Australian study to identify lung cancer-risk
modifying CYP1A1 haplotypes, *2A and *2C variants
were significantly over-represented in NSCLC cases
compared to controls, whereas *4 variant was under-
represented. CYP1A1 haplotypes (in allele order
CYP1A1*4, *2C, *2A); CGC and CG associated with
increased risk of lung cancer confirming CYP1A1 poly-
morphisms as minor risk factor for NSCLC. It was
reported that CYP1A1*2C increase the overall risk of
Table 3 Frequency of CYP1A1 variants in relation to smoking habit in patients and control
CYP1A1 Variant Control Patients Chi-square P-value
Non-smoker Smoker Non-smoker Smoker
N = 120 N = 30 N = 56 N = 93
CYP1A1*2C N (%) 18 (15) 1 (3.3) 7 (12.5) 10 (10.8) 18.9 0.03a
CYP1A1*4 N (%) 29(24.2) 4 (13.3) 15 (26.8) 31 (33.3)
CYP1A1*2C/*4 N (%) 0 (0) 0 (0) 3 (5.4) 1 (1.1)
CYP1A1*1 (wild type) N (%) 73 (60.8) 25 (83.3)a 31 (55.4) 51 (54.8)
aSignificant P
Table 4 Association of CYP1A1 polymorphisms and smoking
with lung cancer risk
CYP1A1
Variant
Non-smokers Smokers OR 95% CI P-value
N = 56 N = 93
N (%) N (%)
CYP1A1*2C 7 (12.5) 10 (10.8) 1.19 (0.42–3.32) 0.75
CYP1A1*4 15 (26.8) 31 (33.3) 0.73 (0.35–1.52) 0.20
CYP1A1*2C/*4 3 (5.4) 1 (1.1) 5.21 (0.53–51.3) 0.12
CYP1A1*1
(wild type)
31 (55.4) 51 (54.8) 0.98 (0.50–1.91) 0.95
Table 5 Distribution of CYP1A1 polymorphisms in heavy (pack
year ≥ 20) vs. light (pack year < 20) smoking in lung cancer
patients and control
CYP1A1 variant Smoking heaviness Likelihood
ratioControl patients
Light heavy Light heavy ratio P-value
N = 16 N = 14 N = 37 N = 56
CYP1A1*2C N
(%)
0 (0) 1 (7) 1 (2.7) 9 (16.1) 15.86 0.07
CYP1A1*4 N
(%)
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NSCLC with an odd ratio of 2.88 (95% CI = 1.70–5.00,
p < 0.001) [38], in accordance with our results in which
CYP1A1*4 and *2C associated with increased risk of
NSCLC by 2 times. On the other hand, San Jose et al.
reported that I462V and T461V increase the risk to
lung cancer in Spanish population, especially to SCLC
[12]. Hung et al. found that I462V associated with
higher risk for lung cancer, especially for lung adeno-
carcinoma [39]. Song et al. noted significantly higher
risk of lung cancer for I462V variant allele, even in the
heterozygous form. However, this elevated risk was
restricted to squamous cell carcinoma only, not for
adenocarcinoma or other histological types of lung can-
cer [21]. In our study, no significant difference of lung
cancer risk for variant alleles between different patho-
logical subtypes of NSCLC. We could not demonstrate
a role of CYP1A1on the stage or the prognosis of the dis-
ease, in agreement with a previous study in Taiwan [40].
Controversial results were obtained from previous
studies on interaction of smoking and CYP1A1 variants.
In the present study CYP1A1*1, wild type, was statisti-
cally more frequent among smoker controls. There was
no association demonstrated between the heterozygous
alleles of CYP1A1 variants, smoking or smoking heavi-
ness in prediction of lung cancer, 75% (3 of 4) of
CYP1A1 combined variant (T461N/ I462V) carriers were
non-smokers.
Smoking was identified as a predominant risk factor
and CYP1A1*2A polymorphism significantly associated
with increased lung cancer risk (OR = 1.69; 95% CI =
1.11–2.59, p = 0.01), whereas CYP1A1*2A and *2C
and Ile105Val imparted increased risk in non-smokers
only [41]. Though, Wenzlaff et al. found no signifi-
cant association with any of CYP1A1 variants in never
smokers [42], a recent pooled analysis by Hung et al.
reported more than 2-fold increase in lung cancer
susceptibility for both CYP1A1*2B and *2C variants
among non-smoker Caucasians [39]. According to
Song et al., non-smokers with CYP1A1*2A variant
had elevated risk than those homozygous for wild
type alleles [21]. Previous study in life-time non-
smoking Chinese women reported an elevated risk of
lung cancer for both CYP1A1*2B and *2C homozy-
gous genotypes, furthermore, lung cancer risk associ-
ated with both polymorphisms was higher in women
with lower environmental tobacco smoke exposure
[43]. I462V polymorphism is not related to lung can-
cer overall, but it might play a role at lower levels of
Tobacco smoking among subjects with impaired car-
cinogen detoxification [44].
Conclusion
Beside the wild type CYP1A1*1, three variants of
CYP1A1 gene were identified in Egyptian population;
CYP1A1*2C, CYP1A1*4 and the rare CYP1A1
c.857 T > C (I286T). Combined variant CYP1A1*2C/
CYP1A1*4 associated with higher risk of lung cancer
specially NSCLC among non-smokers. Identification
of these variants may help in risk assessment, early
detection and improvement of current treatment
options for lung cancer patients. Further studies to
clarify the role of these variants in the pathogenesis
of the disease are needed.
Table 6 Effect of CYP1A1 polymorphisms on lung cancer staging
CYP1A1 gene variant Stage Likelihood P-value
II III IV
N = 25 N = 44 N = 80
CYP1A1*2C N (%) 19 (4) 5 (11) 11(14) 10.22 0.333
CYP1A1*4 N (%) 9 (36) 15 (34) 22 (28)
CYP1A1*2C/*4 N (%) 1 (4) 0 (0) 3 (4)
CYP1A1*1 (wild type) N (%) 14 (56) 24 (55) 44 (55)
Table 7 Effects of CYP1A1 polymorphisms on disease prognosis of available follow up cases
CYP1A1
variant
Response (n = 22) Chi P
Complete response Partial response Progression Refractory disease Regression Stable disease
N (%) N (%) N (%) N (%) N (%) N (%)
CYP1A1*2C 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –
CYP1A1*4 0 (0) 0 (0) 2 (22.2) 0 (0) 1 (25.0) 1 (25.0) 6.8 0.33
CYP1A1*2C/*4 0 (0) 0 (0) 1 (11.1) 0 (0) 0 (0) 0 (0) 3.08 0.79
wild type 2 (100) 2 (100) 6 (66.7) 1 9(100) 3 (75.0) 3 (75.0) 12.2 0.052
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